Oligodendroglial tumors

Seminars in Oncology

Volumn 41, Issue 4, 2014, Pages 468-477

  Jaeckle, Kurt A ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ARTICLE; ASTROCYTOMA; CANCER PATIENT; CANCER PROGNOSIS; CHEMORADIOTHERAPY; CHROMOSOME 19Q; CHROMOSOME 1P; GENE DELETION; GENE MUTATION; HUMAN; IDH1 GENE; OLIGODENDROGLIOMA; ONCOGENE; OVERALL SURVIVAL; PATHOGENESIS; PRIORITY JOURNAL; RARE DISEASE; ADJUVANT THERAPY; BRAIN NEOPLASMS; COGNITION; GENETIC ASSOCIATION; GENETICS; MOLECULAR DIAGNOSIS; QUALITY OF LIFE;

ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; COGNITION; GENETIC ASSOCIATION STUDIES; HUMANS; MOLECULAR DIAGNOSTIC TECHNIQUES; OLIGODENDROGLIOMA; QUALITY OF LIFE; RADIOTHERAPY, ADJUVANT;

EID: 84906729202     PISSN: 00937754     EISSN: 15328708     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2014.06.009     Document Type: Article

References (71)

1. Q.T. Ostrom, H. Gittleman, P. Forah, A. Ondracek, Y. Chen, and Y. Wolinsky et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2006-2010 Neurooncology 15 2013 1 56
2. R.S. Youland, P.D. Brown, C. Giannini, I.F. Parenty, J.H. Uhm, and N.N. Laack Adult low grade glioma: 19-year experience at a single institution Am J Clin Oncol 36 2013 612 619
3. K.A. Jaeckle, P.A. Decker, K.V. Ballman, P.J. Flynn, C. Giannini, and B.W. Scheithauer et al. transformation of low grade glioma and correlation with outcome: an NCCTG database analysis J Neurooncol 104 2011 253 259
4. H.L. Chen, L.J. Chew, R.J. Packer, and V. Gallo Modulation of the Wnt/beta-catnin pathway in human oligodendroglioma cells by Sox17 regulates proliferation and differentiation Cancer Lett 335 2013 361 371
5. G. Marucci, E. Di Oto, A. Farnedi, R. Panzacchi, C. Ligorio, and M.P. Foschini Nogo-A: a useful marker for the diagnosis of oligodendroglioma and for identifying 1p19q co-deletion Hum J Pathol 43 2012 374 380
6. A. Nayak, A.M. Ratte, M.C. Shama, V.P. Singh, A.K. Mahapatra, and V.S. Mehta et al. p53 protein alterations in adult astrocytic tumors and oligodendrogliomas Neurol India 52 2004 (2280-32)
7. Y. Okita, Y. Narita, Y. Miyakita, M. Ohno, Y. Matsushita, and S. Fukushima et al. IDH 1/2 mutation is a prognostic marker for survival and predicts response to chemotherapy for grade II gliomas concomitantly treated with radiation therapy Int J Oncol 41 2012 1325 1336
8. Y.H. Kim, S. Nobusawa, M. Mittelbronn, W. Paulus, B. Brokinkel, and K. Keyvani et al. Molecular classification of low-grade gliomas Am J Pathol 177 2010 2708 2714
9. Y.H. Kim, N. Nonoguchi, W. Paulus, B. Brokinkel, K. Keyvani, and U. Sure et al. Frequent BRAF gain in low-grade diffuse gliomas with 1p/19q loss Brain Pathol 22 2012 834 840
10. R.T. Jenkins, Y. Xiao, H. Sicotte, P.A. Decker, T.M. Kollmeyer, and H.M. Hansen et al. A low frequency variant at 8q24.21 is strongly associated with risk of oligodendroglial tumors and astrocytomas with IDH1 or IDH2 mutation Nat Genet 44 2012 1122 1125
11. V. Suri, P. Jha, S. Agarwal, P. Pathak, M.C. Sharma, and V. Sharma et al. Molecular profile of oligodendrogliomas in young patients Neurooncology 13 2011 1099 1106
12. C. Giannini, P.C. Burger, B.A. Berkey, J.G. Cairncross, R.B. Jenkins, and M. Mehta et al. Anaplastic oligodendroglial tumors: refining the correlation among histopathology, 1p19q deletion and clinical outcome in Intergroup Radiation Therapy Oncology Group trial 9402 Brain Pathol 18 2008 360 369
13. G. Cairncross, M. Wang, E. Shaw, R. Jenkins, D. Brachman, and J. Buckner et al. Phase III trial of chemotherapy for anaplastic oligodendroglioma: long term results of RTOG 9402 J Clin Oncol 20 2013 337 343
14. M.J. van den Bent, A.A. Brandes, M.J. Taphoorn, J.M. Kros, M.C. Kouwenhoven, and J.Y. Delattre et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long term follow-up of EORTC Brain Tumor Group study 26951 J Clin Oncol 31 2013 344 350
15. G. Minniti, A. Sarcella, C. Scaringi, G. Lanzetta, D. Di Stefano, and S. Scarpino et al. Chemoradiation for anaplastic oligodendrogliomas: clinical outcomes and prognostic value of molecular markers J Neurooncol 116 2014 275 282
16. C.V. Zhang, Z.S. Bao, H.J. Wang, W. Yan, Y.W. Liu, and M.Y. Li et al. Correlation of IDH 1/2 mutation with clinicopathologic factors and prognosis in anaplastic gliomas: a report of 203 patients from China J Cancer Res Clin Oncol 140 2014 45 51
17. H.H. Jiang, X.H. Ren, Z. Zhang, and S. Lin A molecular classification system for anaplastic glioma Zhounghua Wai Ke Za Zhi 51 2013 1104 1109
18. M.J. Van den Bent, H.J. Dubbink, Y. Marie, A.A. Brandes, M.J. Taphoorn, and P. Wesseling et al. IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglioma tumors: a report of the European Organization for Research and Treatment of Cancer brain tumor group Clin Cancer Res 16 2010 1597 1604
19. M.J. Van den Bent, H.J. Dubbink, M. Sanson, C.R. van der Lee-Haarloo, M. Hegi, and J.W. Jeuken et al. MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951 J Clin Oncol 10 2009 5881 5886
20. R.B. Jenkins, H. Blair, K.V. Ballman, C. Giannini, R.M. Arusell, and M. Law et al. A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma Cancer Res 66 2006 9852 9861
21. S.M. Dong, J.C. Pang, W.S. Poon, J. Hu, K.F. To, and A.R. Chang et al. Concurrent hypermethylation of multiple genes is associated with grade of oligodendroglial tumors J Neuropathol Exp Neurol 60 2001 808 816
22. P. Mur, M. Mollejo, Y. Ruano, Á.R. de Lope, C. Fiaño, and J.F. García et al. Co-deletion of 1p and 19q determines distinct gene methylation and expression profiles in IDH-mutated oligodendroglial tumors Acta Neuropathol 126 2013 277 289
23. M. Mollemann, M. Wolter, J. Felsberg, V.P. Collins, and G. Reifenberger Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors Int J Cancer 20 2005 379 385
24. M. Wolter, J. Reifenberger, B. Blaschke, K. Ichimura, E.E. Schmidt, and V.P. Collins et al. Oligodendroglial tumors frequently demonstrate hypermethylation of the CDKN2A (MTSI, p16INK4a), p14ARF and CDKN2B (MTS2, p15INK4b) tumor suppressor genes J Neuropathol Exp Neurol 60 2001 1170 1180
25. T. Watanabe, M. Nakamura, Y. Yonekawa, P. Leihues, and H. Ohgaki Promoter hypermethylation and homozygous deletion of the p14ARF and p16INK4a genes in oligodendrogliomas Acta Neuropathol (Berl.) 101 2001 185 189
26. P. Baumgarten, P.N. Harter, M. Tonjes, D. Capper, A.E. Blank, and F. Sahm et al. Loss of FUBP1 expression in gliomas predicts FUBP1 mutation and is associated with oligodendroglial differentiation, IDH1 mutation and 1p/19q loss of heterozygosity Neuropathol Appl Neurobiol 40 2014 205 216
27. H. Arita, Y. Narita, S. Fukushima, Y. Matsushita, A. Yoshida, and Y. Miyakita et al. Upregulating mutations in the TERT promoter commonly occur in adult malignant gliomas and are strongly associated with total 1p/19q loss Acta Neuropathol 126 2013 267 276
28. F. Ducray, E. Criniere, A. Idbaih, K. Mokhtari, Y. Marie, and S. Paris et al. Alpha-internexin expression identifies 1p19q co-deleted gliomas Neurology 72 2009 156 161
29. K. Mokhtari, F. Ducray, Kros Jm, T. Gorlia, A. Idbaih, and M. Taphoorn et al. Alpha-internexin expression predicts outcome in anaplastic oligodendroglial tumors and may positively impact the efficacy of chemotherapy. European Organization for Research and Treatment of Cancer trial 26951 Cancer 117 2011 3014 3026
30. A. Alentorn, M. Sanson, and A. Idbaih Oligodendrogliomas: new insights from the genetics and perpectives Curr Opin Oncol 24 2012 687 693
31. F. Sahm, C. Koelsche, J. Meyer, S. Pusch, K. Lindenberg, and W. Mueller et al. CIC and FUBP1 mutations in oligodendrogliomas, oligoastrocytomas and astrocytomas Acta Neuropathol 123 2012 853 860
32. S. Yip, Y.S. Butterfield, O. Morozova, S. Chittaranjan, M.D. Blough, and J. An et al. Concurrent CIC mutations, IDH mutations, and 1p/19q loss distinguish oligodendrogliomas from other cancers J Pathol 226 2012 7 16
33. H. Sasaki, M.C. Zlatescu, R.A. Betensky, Y. Ino, J.G. Caircross, and D.N. Louis et al. PTEN is a target of chromosome 10q loss in anaplastic oligodendrogliomas and PTEN alterations are associated with poor prognosis Am J Pathol 159 2001 359 367
34. M. Kamiya, and Y. Nakazato The expression of cell cycle regulatory proteins in oligodendroglial tumors Neuropathology 21 2002 52 65
35. A. Idbaih, E. Criniere, Y. Marie, A. Rouseeau, K. Mokhtari, and M. Kujas et al. Gene amplification is a poor prognostic factor in anaplastic oligodendroglioma Neurooncol 10 2008 540 547
36. J.S. Smith, A. Perry, T.J. Borell, H.K. Lee, J. OFallon, and S.M. Hosek et al. Alteration of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas J Clin Oncol 18 2000 636 645
37. J.S. Smith, X.Y. Wang, J. Qian, S.M. Hosek, B.W. Scheithauer, and R.T. Jenkins et al. Amplification of the platelet-derived growth factor receptor-A (PDGFRA) gene occurs in oligodendrogliomas with grade IV anaplastic features J Neuropathol Exp Neurol 59 2000 495 503
38. B. Wiestler, D. Capper, T. Holland-Letz, A. Korshunov, A. von Deimling, and S.M. Pfister et al. ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis Acta Neuropathol 126 2013 443 451
39. M. Talagas, P. Marcorelles, A. Uguen, S. Redon, I. Quintin-Roue, and S. Costa et al. Identification of a novel population in high-grade oligodendroglial tumors non deleted on 1p/19q using array CGH J Neurooncol 109 2012 405 413
40. M.E. Hegi, R.C. Janzer, V.L. Lambiv, T. Gorlia, M.C. Kouwenhouven, and C. Hartmann et al. Presence of an oligodendroglioma-like component in newly diagnosed glioblastoma identifies a pathogenetically heterogenous subgroup and lacks prognostic value; central pathology review of the EORTC-26951/NCIC-CE.3 trial Acta Neuropathol 123 2012 841 852
41. L. Khalid, M. Carone, N. Dumrongpisutikil, J. Intrapiromkul, D. Bonekamp, and P.B. Barker et al. Imaging characteristics of oligodendrogliomas that predict grade Am J Neuroradiol 33 2012 852 857
42. J.H. Sherman, D.M. Prevedello, L. Shah, P. Raghavan, N. Pouratian, and R.M. Starke et al. MR imaging characteristics of oligodendroglial tumors with assessment of 1p/19q deletion status Acta Neurochir (Wien) 152 2010 1827 1834
43. J.W. Kim, C.K. Park, S.H. Park, Y.H. Kim, J.H. Han, and C.Y. Kim et al. Relationship between radiological characteristics and combined 1p and 19q deletion in World Health Organization grade III oligodendroglial tumours J Neurol Neurosurg Psychiatry 82 2011 2247
44. A.L. Lin, J. Liu, J. Evans, E.C. Leuhardt, K.M. Rich, and R.G. Dacey et al. Co-deletions at 1p and 19q predict a lower risk of pseudoprogression in oligodendrogliomas and mixed oligoastrocytomas Neurooncology 16 2014 123 130
45. N. Shinozaki, Y. Uchino, K. Yoshikawas, T. Matsutani, A. Hasegawa, and N. Saeki et al. Discrimination between low grade oligodendrogliomas and diffuse astrocytomas with the aid of 11C-methionine positron emission tomography J Neurosurg 114 2011 1640 1647
46. H.C. Kang, I.H. Kim, K.Y. Eom, J.H. Kim, and H.W. Jung The role of radiotherapy in the treatment of newly diagnosed supratentorial low grade oligodendrogliomas: a comparative analysis with immediate radiotherapy versus surgery alone Cancer Res Treat 41 2009 132 137
47. Y. Iwadate, T. Matsutani, Y. Hasegawa, N. Shinozaki, Y. Higuchi, and N. Saeki Favorable long-term outcome of low-grade oligodendrogliomas irrespective of 1p/19q status when treated without radiotherapy J Neurooncol 102 2011 442 449
48. E.G. Shaw, M. Wang, S.W. Coons, D.G. Brachman, J.C. Buckner, and K.J. Steltzer et al. Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802 J Clin Oncol 30 2012 3065 3070
49. J. Streffer, M. Schabet, M. Bamberg, E.H. Grote, R. Meyermann, and K. Voigt et al. A role for pre-irradiation PCV chemotherapy for oligodendroglial brain tumors J Neurol 247 2000 297 302
50. N.A. Paleologos, D.R. Macdonald, N.A. Vick, and J.G. Cairncross Neoadjuvant procarbazine, CCNU and vincristine for anaplastic and aggressive oligodendroglioma Neurol 53 1999 1141 1143
51. Y. Iwadate, T. Matsutani, N. Shinozaki, and N. Saeki Anaplastic oligodendroglial tumors harboring 1p/19q deletions can be successfully treated without radiotherapy Anticancer Res 31 2011 4475 4479
52. H.K. Gan, M.A. Rosenthal, A. Dowling, R. Kalnins, E. Algar, and N. Wong et al. A phase II trial of primary temozolomide in patients with grade III oligodendroglial brain tumors Neurooncol 12 2010 500 507
53. T. Mikkelsen, T. Doyble, J. Anderson, J. Margolis, N. Paleologos, and J. Gutierrez et al. Temozolomide single-agent chemotherapy for newly diagnosed anaplastic oligodendroglioma J Neurooncol 92 2009 57 63
54. M.A. Vogelbaum, B. Berkey, D. Peereboom, D. Macdonald, C. Giannini, and J.H. Suh et al. Phase II trial of preirradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: RTOG BR0131 Neurooncology 11 2009 167 175
55. M.A. Vogelbaum, M. Wang, D.R. Peereboom, D.R. Macdonald, C. Giannini, and J.H. Suh et al. Oligodnedrogliomas and mixed anaplastic oligodendrogliomas: updated survival and progression free survival analysis [abstract] Neurooncology 14 suppl6 2012 68 85
56. W. Wick, C. Hartmann, C. Engel, S. Stoffels, J. Felsberg, F. Stockhammer, and M.C. Sabel et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide J Clin Oncol 27 2009 5874 5880
57. F. Ducray, M.S. del Rio, C. Carpentier, D. Psimaras, A. Idbaih, and C. Dehais et al. Up-front temozolomide in elderly patients with anaplastic oligodendroglioma and oligoastrocytoma J Neurooncol 101 2011 457 462
58. D.R. Johnson, A.M. Sawyer, C.A. Meyers, B.P. ONeill, and J.S. Wefel Early measures of cognitive function predict survival in patients with newly diagnosed glioblastoma Neurooncology 14 2012 808 816
59. L.E. Abrey, B.H. Childs, N. Paleologos, L. Kaminer, S. Rosenfeld, and D. Salzman et al. High-dose chemotherapy with stem cell rescue as initial therapy for anaplastic oligodendroglioma: long-term follow-up Neurooncology 8 2006 183 188
60. A. Lassman, F.M. Iwamoto, T.F. Cloughesy, K.D. Aldape, A.L. Rivera, and A.F. Eichler et al. International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors Neurooncology 13 2011 649 659
61. T. Gorlia, J.Y. Delattre, A.A. Brandes, J.M. Kros, M.J. Taphoorn, and M.C. Kouwenhoven et al. New clinical, pathological and molecular prognostic models and calculators in patients with locally diagnosed anaplastic oligodendroglima or oligoastrocytoma. A prognostic factor analysis of European Organisation for Research and Treatment of Cancer brain tumour group study 26951 Eur J Cancer 49 2013 3577 3585
62. A.A. Brandes, A. Tosoni, F. Vastola, L.M. Pasetto, B. Coria, and D. Danieli et al. Efficacy and feasibility of standard procarbazine, lomustine, and vincristine chemotherapy in anaplastic oligodendroglioma and oligoastrocytoma recurrence after radiotherapy. A Phase II study Cancer 101 2004 2079 2085
63. A.A. Brandes, A. Tosoni, G. Cavallo, M. Reni, E. Franceschi, and L. Bonaldi et al. Correlations between 06-methyl guanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a prospective GICNO study J Clin Oncol 24 2006 4746 4753
64. H.S. Gwak, G.T. Yee, C.K. Park, J.W. Kim, Y.K. Hong, and S.G. Kang et al. Temozolomide salvage chemotherapy for recurrent anaplastic oligodendroglioma and oligo-astrocytoma J Korean Neurosurg Soc 54 2013 489 495
65. M.C. Chamberlain, and M.J. Glantz CPT-11 for recurrent temozolomide-refractory 1p19q co-deleted anaplastic oligodendroglioma J Neurooncol 89 2008 231 238
66. L. Scopece, E. Farnceshchi, G. Cavallo, A. Paioli, G. Paioli, and R. Conforti et al. Carboplatin and etoposide (CE) chemotherapy in patients with recurrent or progressive oligodendroglioma tumors J Neurooncol 79 2006 299 305
67. M.C. Chamberlain, and S. Johnston Bevacizumab for recurrent alkylator-refractory anaplastic oligodendroglioma Cancer 115 2009 1734 1743
68. S. Taillibert, L.A. Vincent, and B. Granger Bevacizumab and irinotecan for recurrent oligodendroglioma tumors Neurology 72 2009 1601 1606
69. K.A. Jaeckle, S.K. Anderson, M. Kosel, J. Sarkaria, P. Brown, and P.J. Flynn et al. NCCTG N0272: Phase I-II trial of imatinib mesylate (Gleevec, STI571) in treatment of recurrent oligodendroglioma and mixed oligoastrocytoma [abstract] Neurooncology 13 2011 85 91
70. E.J. Habets, M.J. Taphoorn, S. Nederend, M. Klein, D. Delgadillo, and K. Hoang-Xuan et al. Health-related quality of life and cognitive functioning in long term anaplastic oligodendroglioma and oligoastrocytoma survivors J Neurooncol 116 2014 161 168
71. M. Wang, G. Cairncross, E. Shaw, R. Jenkins, B. Scheithauer, and D. Brachman et al. Cognition and quality-of-life after chemotherapy plus radiotherapy (RT) versus RT for pure and mixed anaplastic oligodendrogliomas: Radiation Therapy Oncology Group trial 9402 Int J Radiat Oncol Biol Phys 77 2012 662 669